Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages

Background Regorafenib and other multikinase inhibitors may enhance antitumor efficacy of anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its immunomodulatory effects, besides anti-angiogenesis, were not clearly defined.Methods In vivo antitumor efficacy was tested in...

Full description

Bibliographic Details
Main Authors: Ann-Lii Cheng, Da-Liang Ou, Chia-Wei Chen, Chia-Lang Hsu, Chih-Hung Chung, Zi-Rui Feng, Bin-Shyun Lee, Muh-Hwa Yang, Chiun Hsu
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e001657.full

Internet

https://jitc.bmj.com/content/9/3/e001657.full

Similar Items